Herbs (Global Traditional) · Native American
Grindelia (Grindelia robusta) (Grindelia robusta)
Moderate Evidencebotanical2 PubMed Studies
Hermetica Superfood Encyclopedia
Grindelia robusta is a medicinal plant containing diterpenes and flavonoids that provides respiratory inflammation support. Research shows its extract reduces inflammatory cytokines including IL-8, TNF-α, and IL-1β in bronchial epithelial cells at concentrations of 25-100 μg/ml.
Grindelia robusta (gumweed) is a perennial herb native to western North America, belonging to the Asteraceae family. The aerial parts (leaves and flowering tops) are harvested during flowering and typically extracted using 80% ethanol or enriched for saponins and polyphenols via hydromethanolic methods. The herb contains triterpenoid saponins (including grindelic acid), polyphenols, and diterpenes as primary bioactive compounds.
No controlled human clinical trials, RCTs, or meta-analyses exist for Grindelia robusta or G. squarrosa preparations. Available research consists of in vitro studies including PMID: 33536899 (LPS-stimulated epithelial cells) and PMID: 21031629 (macrophage inflammation models), plus animal studies showing 41-63% reduction in carrageenan-induced paw edema at 100-200 mg/kg oral doses in rats.
No clinically studied human dosages are available. Preclinical studies used: dry extract (80% ethanol) at 100-200 mg/kg orally in rats; in vitro extracts at 25-100 μg/ml; or 50 μM grindelic acid. Standardization typically targets saponin or polyphenol content. Consult a healthcare provider before starting any new supplement.
Grindelia (Grindelia robusta) is a medicinal herb, not a significant dietary source of macronutrients or micronutrients; its profile is dominated by bioactive phytochemicals rather than conventional nutritional components. Macronutrient content is negligible in typical medicinal preparations (tinctures, extracts, dried herb). Key bioactive compounds include: (1) Diterpene acids (grindelic acid and related labdane-type diterpenoids, estimated 1-3% of dry weight aerial parts) — the primary resinous constituents responsible for much of its biological activity; (2) Flavonoids including quercetin, luteolin, and kaempferol glycosides (approximately 0.5-2% total flavonoids by dry weight), contributing antioxidant and anti-inflammatory effects; (3) Phenolic acids such as caffeic acid and chlorogenic acid (reported in the range of 0.1-0.5% dry weight); (4) Saponins (triterpenoid type, ~1-2% dry weight); (5) Essential oils containing monoterpenes (borneol, bornyl acetate, limonene) and sesquiterpenes (~0.2-0.5% in aerial parts); (6) Tannins (condensed and hydrolyzable, estimated 2-5% dry weight); (7) Polysaccharides with potential immunomodulatory properties (quantities not precisely characterized in literature). Mineral content of dried aerial parts includes modest levels of calcium (~500-800 mg/100g dry), potassium (~1000-1500 mg/100g dry), and magnesium (~150-250 mg/100g dry), though these are not nutritionally relevant at medicinal doses. Bioavailability notes: Diterpene acids and flavonoids show moderate oral bioavailability enhanced by the herb's resinous matrix; tincture preparations (ethanol-based, typically 1:5 ratio) improve extraction of lipophilic diterpenes relative to aqueous preparations; standardization of commercial extracts is not yet uniform, limiting precise dosing of active constituents. Data on precise concentrations of individual compounds in standardized extracts remains limited in peer-reviewed literature as of available research.
Grindelia robusta's diterpene compounds inhibit pro-inflammatory cytokine production including IL-8, TNF-α, IL-1β, and IL-6 in nasal and bronchial epithelial cells. The extract modulates inflammatory pathways in respiratory tissue, demonstrating anti-inflammatory activity comparable to the corticosteroid budesonide. Its flavonoid constituents may contribute additional antioxidant effects that support respiratory epithelial cell protection.
Current evidence for Grindelia robusta is limited to preliminary in vitro studies on respiratory inflammation. Laboratory research shows extract concentrations of 25-100 μg/ml significantly reduced inflammatory cytokines in nasal and bronchial epithelial cell cultures, with effects comparable to budesonide treatment. No published human clinical trials have evaluated Grindelia's therapeutic efficacy or safety profile. The existing preclinical data suggests potential for respiratory applications but requires validation through controlled human studies.
Safety data for Grindelia robusta supplementation is currently limited due to lack of clinical trials. Traditional use suggests generally good tolerance, but potential side effects, optimal dosing, and long-term safety remain unstudied. No specific drug interactions have been documented, though caution is advised when combining with respiratory medications or anti-inflammatory drugs. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
